Holen Sie sich die Stockscreener-App
4.43
4.73%
-0.22
Schlusskurs vom Vortag:
$4.65
Offen:
$4.66
24-Stunden-Volumen:
819.50K
Relative Volume:
0.62
Marktkapitalisierung:
$253.33M
Einnahmen:
$5.82M
Nettoeinkommen (Verlust:
$71.18M
KGV:
4.4424
EPS:
0.9972
Netto-Cashflow:
$-84.30M
1W Leistung:
-10.32%
1M Leistung:
-17.50%
6M Leistung:
-17.66%
1J Leistung:
-19.01%
1-Tages-Spanne:
$4.39
$4.66
1-Wochen-Bereich:
$4.28
$4.945
52-Wochen-Spanne:
$4.00
$7.65
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Firmenname
Abeona Therapeutics Inc
Sektor
Branche
Telefon
646-813-4701
Adresse
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
4.43 | 253.33M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-17 | Eingeleitet | Roth Capital | Buy |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-03-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-30 | Eingeleitet | Stifel | Buy |
| 2020-11-11 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-02-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-12-10 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2019-08-15 | Herabstufung | Maxim Group | Buy → Hold |
| 2019-08-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-06-27 | Eingeleitet | Mizuho | Buy |
| 2018-10-12 | Eingeleitet | Mizuho | Buy |
| 2018-06-05 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-11-08 | Eingeleitet | SunTrust | Buy |
| 2017-10-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-10-10 | Eingeleitet | Citigroup | Buy |
| 2017-10-05 | Bestätigt | Maxim Group | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-18 | Bestätigt | Maxim Group | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-01-06 | Eingeleitet | Jefferies | Buy |
| 2016-09-29 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Abeona Therapeutics Inc Aktie (ABEO) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc.ABEO - GlobeNewswire Inc.
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Two new hires' awards cover up to 7,200 Abeona shares, which become theirs over three years if they stay. - Stock Titan
Form 4 Abeona Therapeutics Inc For: 29 September By Investing.com - Investing.com South Africa
Form 4 Abeona Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Abeona Therapeutics CEO Seshadri sells $101,091 in shares By Investing.com - Investing.com South Africa
Abeona Therapeutics CEO Seshadri sells $101,091 in shares By Investing.com - Investing.com Nigeria
Abeona Therapeutics CFO Joseph Vazzano sells $47,385 in company stock - Investing.com
Abeona Therapeutics CEO Seshadri sells $101,091 in shares - Investing.com
Abeona Therapeutics CFO Joseph Vazzano sells $47,385 in company stock By Investing.com - Investing.com South Africa
Abeona Therapeutics SVP sells $34,681 in company stock By Investing.com - Investing.com South Africa
Abeona Therapeutics SVP sells $34,681 in company stock - Investing.com
Abeona Therapeutics CCO Madhav sells $25,272 in stock - Investing.com
Abeona Therapeutics CCO Madhav sells $25,272 in stock By Investing.com - Investing.com Canada
To cover stock-award taxes, Abeona Therapeutics (ABEO) CFO sells 9,191 shares. - Stock Titan
To cover stock-award taxes, Abeona Therapeutics (ABEO) legal chief sold 6,727 shares. - Stock Titan
To cover stock-award taxes, Abeona Therapeutics (ABEO) CEO sells 19,608 shares. - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc.ABEO - GlobeNewswire Inc.
To cover taxes on vested stock, an Abeona Therapeutics (ABEO) officer lists shares valued at $47,385 for sale. - Stock Titan
Tax coverage after share vesting: an Abeona Therapeutics (ABEO) officer lists 19,608 shares for sale. - Stock Titan
Tax-related share sale: Abeona Therapeutics (ABEO) lists an officer’s shares for sale at a $34,682 value - Stock Titan
Abeona Therapeutics (NasdaqCM:ABEO) Stock Forecast & Analyst Predictions - Simply Wall Street
Abeona Therapeutics (NASDAQ: ABEO) posts new deck for H.C. Wainwright conference - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc.ABEO - PR Newswire
Abeona at Cantor healthcare conference: slow launch, big rare-disease bet - Investing.com Canada
Abeona at Cantor healthcare conference: slow launch, big rare-disease bet - Investing.com
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc.ABEO - FinancialContent
Don't Ignore The Insider Selling In Abeona Therapeutics - simplywall.st
Responsive Playbooks and the ABEO Inflection - Stock Traders Daily
Abeona Therapeutics director Mark Alvino sells $87,966 in shares By Investing.com - Investing.com Australia
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Abeona Therapeutics director Mark Alvino sells $87,966 in shares By Investing.com - Investing.com Canada
Abeona Therapeutics director Mark Alvino sells $87,966 in shares By Investing.com - Investing.com Nigeria
Abeona Therapeutics director Mark Alvino sells $87,966 in shares By Investing.com - Investing.com India
Abeona Therapeutics director Mark Alvino sells $87,966 in shares - Investing.com
Abeona Therapeutics director Mark Alvino sells $87,966 in shares By Investing.com - Investing.com UK
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - kdhnews.com
Director Mark Alvino Sells 15,000 Shares of Abeona Therapeutics Inc (ABEO) - GuruFocus
Abeona Therapeutics (ABEO) director sells 15,000 shares, still holds 62,065 - Stock Titan
Director plans Abeona (NASDAQ: ABEO) stock sale from equity awards - Stock Titan
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Stock Titan
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Abeona Therapeutics faces securities fraud prob... - Pluang
H.C. Wainwright Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Abeona (ABEO) Stock: Gains 2.18% to Reach $6.09 in the Latest Reading; Range Check: the Supplied Trading Band Runs From $5.79 to $6.39 for the Current SessionCatalyst Driven Stocks - vinanet.vn
High Insider Ownership Growth Stocks To Watch In August 2026 - simplywall.st
Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement Milestone - Yahoo Finance
Abeona (ABEO) Latest Quarter: EPS Misses Its Estimate in the Latest Session; Market Reaction: The Market Price Declines 2.77% for the Current SessionRevenue Growth Outlook - vinanet.vn
Abeona (ABEO) Q2 2026 Earnings Call Transcript - AOL.com
Finanzdaten der Abeona Therapeutics Inc-Aktie (ABEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Abeona Therapeutics Inc-Aktie (ABEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Seshadri Vishwas | Officer |
Sep 29 '26 |
Proposed Sale |
5.16 |
19,608 |
101,091 |
0 |
| Vazzano Joseph Walter | Officer |
Sep 29 '26 |
Proposed Sale |
5.16 |
9,191 |
47,385 |
0 |
| Vasanthavada Madhav | Chief Commercial Officer |
Sep 29 '26 |
Sale |
5.16 |
4,902 |
25,273 |
285,721 |
| O'Malley Brendan M. | SVP, Chief Legal Officer |
Sep 29 '26 |
Sale |
5.16 |
6,727 |
34,682 |
421,226 |
| Vazzano Joseph Walter | Chief Financial Officer |
Sep 29 '26 |
Sale |
5.16 |
9,191 |
47,385 |
482,888 |
| O'Malley Brendan M. | Officer |
Sep 29 '26 |
Proposed Sale |
5.16 |
6,727 |
34,682 |
0 |
| Vasanthavada Madhav | Officer |
Sep 29 '26 |
Proposed Sale |
5.16 |
4,902 |
25,273 |
0 |
| Alvino Mark | Director |
Sep 01 '26 |
Proposed Sale |
5.86 |
15,000 |
87,966 |
0 |
| Alvino Mark | Director |
Sep 01 '26 |
Sale |
5.86 |
15,000 |
87,966 |
62,065 |
| Vazzano Joseph Walter | Chief Financial Officer |
Jul 21 '26 |
Sale |
6.53 |
1,478 |
9,651 |
492,079 |
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):